Anxiety News and Research

Latest Anxiety News and Research

Yo-yo dieting and sugar-bingeing can lead to anxiety and withdrawal symptoms

In research that sheds light on the perils of yo-yo dieting and repeated bouts of sugar-bingeing, researchers from The Scripps Research Institute have shown in animal models that cycling between periods of eating sweet and regular-tasting food can activate the brain's stress system and generate overeating, anxiety, and withdrawal-like symptoms.

10 Nov 2009

Survey finds fewer Americans use therapy to manage stress

Results of a recent survey reveal that, despite an increase in stress, fewer Americans use therapy as a way to manage it.

9 Nov 2009

Women with asthma find it harder to sleep and feel more tired during the day than men

Women with asthma are more anxious, find it harder to sleep and are more tired during the day than their male counterparts, but nevertheless tend to be better at following their treatment, reveals a thesis from the Sahlgrenska Academy at the University of Gothenburg in close collaboration with Sahlgrenska University Hospital.

9 Nov 2009

Study finds brain changes and severe depression in political detainees experiencing head injury

Depression and other emotional symptoms in survivors of torture and other traumatic experiences may be exacerbated by the effects of head injuries, according to a study from the Harvard Program in Refugee Trauma (HPRT), based in the Massachusetts General Hospital (MGH) Department of Psychiatry.

7 Nov 2009

Prescription drug abuse among teens: NCPIE, SAMHSA launches campaign

The National Council on Patient Information and Education (NCPIE), along with the Substance Abuse and Mental Health Services Administration (SAMHSA) and representatives from 15 nationally recognized prevention, health professional and child advocacy organizations, are launching Maximizing Your Role as a Teen Influencer: What You Can Do to Help Prevent Teen Prescription Drug Abuse.

6 Nov 2009

Cereplast confirms that all its resins are made without the use of BPA

Cereplast, Inc., a leading manufacturer of proprietary bio-based, sustainable plastics, confirmed today that all its resins are made without the use of Bisphenol A, commonly referred to as BPA. All products made with both Cereplast resin families, including the Compostables® and the Hybrids® are BPA free.

5 Nov 2009

US military veteran shares his views and experience in military service

A pediatric cardiologist - - not necessarily the kind of doctor you think would be stationed with a battalion of Marines in one of the most volatile areas of Iraq. But for nearly a year in 2003-2004 that is exactly where Joel Hardin, M.D., pediatric cardiologist, found himself. Embedded with the 3rd Battalion, 24th Marines he brought medical care to soldiers as well as Iraqis.

5 Nov 2009

CHANTIX/CHAMPIX raises hope for quitting smoking

New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP).

5 Nov 2009

Bursting common myths about psoriasis

Psoriasis is a real disability that affects approximately one million Canadians. A recent Canadian survey found that the causes and effects of this chronic, recurrent skin disorder are often misunderstood - and the result of these misperceptions can leave a lasting negative impact on those who suffer from this debilitating immune system disease.

5 Nov 2009

Poor housing conditions can lead to chronic disease and premature death

Being warm enough at home might lead to better health, according to a new review appearing online in the American Journal of Public Health.

5 Nov 2009

Work is causing stress for more Seattleites, reveals APA survey

Work is causing stress for more Seattleites this year according to the American Psychological Association's (APA) Stress in America survey, while the number reporting money or the economy as significant stressors has dropped since last year. More than 50 percent of city residents remain stressed by one or more of these three sources, a cause of concern for psychologists who worry about the effects of long-term stress and how it can contribute to chronic health disorders.

4 Nov 2009

Work, money and job stability are significant sources of stress for Denver residents

More Denver residents say that their work, money and job stability are significant sources of stress than Americans nationwide, according to the American Psychological Association's (APA) Stress in America survey.

4 Nov 2009

Pfizer and Medivation initiate dimebon trials in patients with Alzheimer’s disease

Pfizer Inc and Medivation, Inc. today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD).

4 Nov 2009

More Atlanta residents are stressed about the economy according to APA survey

More Atlanta residents are stressed about the economy this year according to the American Psychological Association's (APA) Stress in America survey, while the number of Atlantans reporting money or work as significant stressors in 2009 has dropped. More than 60 percent of city residents continue to report that money, work and the economy are significant sources of stress -- a cause of concern for psychologists who worry about the effects of long-term stress and how it can contribute to chronic health disorders.

4 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Individuals who had experienced trauma exposure in both childhood and adulthood likely to develop PTSD

Individuals who experience both childhood adversity and traumatic events in adulthood appear more likely to develop post-traumatic stress disorder than those exposed to only one of these types of incidents, according to a report in the November issue of Archives of General Psychiatry, one of the JAMA/Archives journals. In addition, the risk was further increased in individuals with a certain genetic mutation.

3 Nov 2009

Seaside Therapeutics commences STX107 Phase 1 clinical trial for Fragile X Syndrome

Seaside Therapeutics LLC today announced that the Company has initiated a Phase 1 clinical trial of STX107, a highly potent, selective mGluR5 antagonist, in development for the treatment of Fragile X Syndrome. The single ascending dose study is designed to evaluate the safety, tolerability and pharmacokinetics of STX107 in healthy volunteers. Fragile X Syndrome is the most common inherited form of mental impairment and the most common known cause of autism.

3 Nov 2009

Sexual relationships were significantly affected after a stroke, says study

Dr Assumpta Ryan and Hilary Thompson recently published findings from a study involving 16 married stroke survivors - nine males and seven females - aged between 33 and 78.

3 Nov 2009

Phase 1 study of STX107 for Fragile X syndrome begins

NIH-supported scientists at Seaside Therapeutics in Cambridge, Mass., are beginning a clinical trial of a potential medication designed to correct a central neurochemical defect underlying Fragile X syndrome, the most common inherited cause of intellectual disability. There has to date been no medication that could alter the disorder's neurologic abnormalities. The study will evaluate safety, tolerability, and optimal dosage in healthy volunteers.

3 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009